Viewing StudyNCT04331626



Ignite Creation Date: 2024-05-06 @ 2:30 PM
Last Modification Date: 2024-10-26 @ 1:31 PM
Study NCT ID: NCT04331626
Status: UNKNOWN
Last Update Posted: 2020-04-02
First Post: 2020-03-31

Brief Title: Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Sponsor:
Organization: Henan Cancer Hospital

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 50
Enrollment Type: ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE4
Observational Models:
Time Perspective List:
Who Masked List: